Type 2 diabetes mellitus (T2DM) is a prevalent disease involving several clinical implications, including renal, vascular, and metabolic complications. Therapies focusing on glycemic control in T2DM have largely failed to improve cardiovascular (CV) and kidney outcomes substantially. This has accentuated the need for new treatment strategies for reno-CV protection in T2DM patients.1 In recent years, compelling evidence is available for new-age antidiabetic drugs; the sodium-glucose co-transporter 2- inhibitors (SGL2-i) demonstrating cardioprotective and renoprotective effects.2 In this regard, Boehringer Ingelheim India and Docplexus have organized a panel discussion on 22nd January 2020 from 03:00 PM IST onwards.
In this webinar, the expert panel will discuss the renal-vascular-metabolic conundrum in T2DM and the lessons learned with SGLT2-i. We invite you to share your questions,…